edoc

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

Mitchell, P. and Korobelnik, J.-F. and Lanzetta, P. and Holz, F. G. and Prünte, C. and Schmidt-Erfurth, U. and Tano, Y. and Wolf, S.. (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British journal of ophthalmology, Vol. 94, no. 1. pp. 2-13.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003349

Downloads: Statistics Overview

Abstract

Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialfächer (Klinik) > Ophthalmologie USB
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialfächer (Klinik) > Ophthalmologie USB
UniBasel Contributors:Prünte, Christian
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Pulman
ISSN:0007-1161
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:24 May 2013 09:22
Deposited On:24 May 2013 09:12

Repository Staff Only: item control page